10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ABUS (Arbutus Biopharma Corp) Stock Analysis
Buy, Hold or Sell?

Let's analyze Arbutus Biopharma Corp together

I guess you are interested in Arbutus Biopharma Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Arbutus Biopharma Corp’s Financial Insights
  • 📈 Technical Analysis (TA) – Arbutus Biopharma Corp’s Price Targets

I'm going to help you getting a better view of Arbutus Biopharma Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Arbutus Biopharma Corp

I send you an email if I find something interesting about Arbutus Biopharma Corp.

1. Quick Overview

1.1. Quick analysis of Arbutus Biopharma Corp (30 sec.)










1.2. What can you expect buying and holding a share of Arbutus Biopharma Corp? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
37.5%

What is your share worth?

Current worth
$0.43
Expected worth in 1 year
$0.22
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$-0.21
Return On Investment
-4.7%

For what price can you sell your share?

Current Price per Share
$4.43
Expected price per share
$3.79 - $
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Arbutus Biopharma Corp (5 min.)




Live pricePrice per Share (EOD)
$4.43
Intrinsic Value Per Share
$-2.72 - $-1.36
Total Value Per Share
$-2.29 - $-0.93

2.2. Growth of Arbutus Biopharma Corp (5 min.)




Is Arbutus Biopharma Corp growing?

Current yearPrevious yearGrowGrow %
How rich?$82.9m$115.6m-$24m-26.2%

How much money is Arbutus Biopharma Corp making?

Current yearPrevious yearGrowGrow %
Making money-$13.5m-$19.2m$5.7m42.1%
Net Profit Margin-908.9%-911.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Arbutus Biopharma Corp (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#345 / 853

Most Revenue
#358 / 853

Most Profit
#562 / 853

Most Efficient
#642 / 853
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Arbutus Biopharma Corp?

Welcome investor! Arbutus Biopharma Corp's management wants to use your money to grow the business. In return you get a share of Arbutus Biopharma Corp.

First you should know what it really means to hold a share of Arbutus Biopharma Corp. And how you can make/lose money.

Speculation

The Price per Share of Arbutus Biopharma Corp is $4.43. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Arbutus Biopharma Corp.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Arbutus Biopharma Corp, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.43. Based on the TTM, the Book Value Change Per Share is $-0.05 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Arbutus Biopharma Corp.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.010.3%-0.07-1.6%-0.10-2.3%-0.09-2.0%-0.10-2.1%-0.17-3.8%
Usd Book Value Change Per Share0.020.4%-0.05-1.2%-0.02-0.4%-0.03-0.7%0.000.1%-0.07-1.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.010.3%0.010.3%
Usd Total Gains Per Share0.020.4%-0.05-1.2%-0.02-0.4%-0.03-0.7%0.020.4%-0.05-1.2%
Usd Price Per Share3.09-3.43-2.55-2.79-3.02-3.52-
Price to Earnings Ratio58.91-7.56--6.36--1.74--4.30-9.23-
Price-to-Total Gains Ratio168.43-4.61-17.96-2.10--5.05-33.94-
Price to Book Ratio7.16-7.24-4.23-4.92-5.04-4.45-
Price-to-Total Gains Ratio168.43-4.61-17.96-2.10--5.05-33.94-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.43
Number of shares225
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.050.00
Usd Total Gains Per Share-0.050.02
Gains per Quarter (225 shares)-11.674.02
Gains per Year (225 shares)-46.6916.07
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-47-571246
20-93-10424822
30-140-151361238
40-187-198481654
50-233-245602070
60-280-292722486
70-327-3398428102
80-374-3869632118
90-420-43310836134
100-467-48012040150

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%2.038.00.05.0%10.069.023.09.8%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%9.011.00.045.0%13.027.00.032.5%35.067.00.034.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%6.00.014.030.0%15.00.025.037.5%15.00.087.014.7%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%9.011.00.045.0%14.026.00.035.0%36.066.00.035.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Arbutus Biopharma Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.018-0.052+383%-0.016+187%-0.031+267%0.004+310%-0.066+460%
Book Value Per Share--0.4310.477-10%0.603-28%0.604-29%0.632-32%0.959-55%
Current Ratio--20.53310.428+97%6.367+222%7.455+175%9.310+121%11.412+80%
Debt To Asset Ratio--0.1960.255-23%0.246-20%0.256-23%0.252-22%0.238-18%
Debt To Equity Ratio--0.2450.347-30%0.327-25%0.347-30%0.340-28%0.320-24%
Dividend Per Share----0%-0%-0%0.013-100%0.012-100%
Enterprise Value--672312174.970740904412.463-9%583952470.400+15%625711669.834+7%668586067.165+1%750122449.310-10%
Eps--0.013-0.071+640%-0.101+867%-0.089+777%-0.095+825%-0.169+1392%
Ev To Ebitda Ratio--65.6048.116+708%-7.758+112%-2.542+104%-6.203+109%-9.553+115%
Ev To Sales Ratio--15.65197.514-84%72.237-78%64.506-76%64.039-76%111.852-86%
Free Cash Flow Per Share---0.082-0.079-4%-0.093+14%-0.094+15%-0.081-1%-0.080-2%
Free Cash Flow To Equity Per Share---0.080-0.070-12%-0.024-70%-0.048-40%0.003-2598%-0.015-81%
Gross Profit Margin--1.0001.0000%1.014-1%1.0050%1.0030%1.0010%
Intrinsic Value_10Y_max---1.358----------
Intrinsic Value_10Y_min---2.722----------
Intrinsic Value_1Y_max---0.294----------
Intrinsic Value_1Y_min---0.360----------
Intrinsic Value_3Y_max---0.764----------
Intrinsic Value_3Y_min---1.012----------
Intrinsic Value_5Y_max---1.088----------
Intrinsic Value_5Y_min---1.584----------
Market Cap849226605.440+30%594515174.970657110412.463-10%488832470.400+22%534860919.834+11%578847567.165+3%675289924.310-12%
Net Profit Margin--0.235-9.089+3969%-9.114+3979%-7.115+3128%-6.778+2985%5.667-96%
Operating Margin--0.238-9.074+3920%-9.094+3928%-7.089+3084%-6.634+2893%-11.374+4888%
Operating Ratio--0.82212.136-93%13.250-94%9.895-92%10.226-92%18.619-96%
Pb Ratio10.272+30%7.1657.240-1%4.233+69%4.915+46%5.037+42%4.451+61%
Pe Ratio84.456+30%58.9107.557+680%-6.360+111%-1.738+103%-4.297+107%9.231+538%
Price Per Share4.430+30%3.0903.425-10%2.550+21%2.789+11%3.019+2%3.522-12%
Price To Free Cash Flow Ratio-13.530-43%-9.437-11.473+22%-7.152-24%-8.049-15%-8.029-15%-12.435+32%
Price To Total Gains Ratio241.477+30%168.4344.614+3551%17.959+838%2.096+7936%-5.052+103%33.943+396%
Quick Ratio--31.83816.758+90%10.509+203%12.308+159%13.981+128%17.343+84%
Return On Assets--0.024-0.105+531%-0.126+615%-0.109+545%-0.109+546%-0.134+647%
Return On Equity--0.030-0.148+587%-0.167+649%-0.148+588%-0.147+583%-0.180+691%
Total Gains Per Share--0.018-0.052+383%-0.016+187%-0.031+267%0.018+3%-0.054+394%
Usd Book Value--82976000.00091597250.000-9%115611500.000-28%115817666.667-28%121133350.000-32%183868775.000-55%
Usd Book Value Change Per Share--0.018-0.052+383%-0.016+187%-0.031+267%0.004+310%-0.066+460%
Usd Book Value Per Share--0.4310.477-10%0.603-28%0.604-29%0.632-32%0.959-55%
Usd Dividend Per Share----0%-0%-0%0.013-100%0.012-100%
Usd Enterprise Value--672312174.970740904412.463-9%583952470.400+15%625711669.834+7%668586067.165+1%750122449.310-10%
Usd Eps--0.013-0.071+640%-0.101+867%-0.089+777%-0.095+825%-0.169+1392%
Usd Free Cash Flow---15749000.000-15069250.000-4%-17920855.408+14%-17975285.136+14%-15567771.082-1%-15374210.541-2%
Usd Free Cash Flow Per Share---0.082-0.079-4%-0.093+14%-0.094+15%-0.081-1%-0.080-2%
Usd Free Cash Flow To Equity Per Share---0.080-0.070-12%-0.024-70%-0.048-40%0.003-2598%-0.015-81%
Usd Market Cap849226605.440+30%594515174.970657110412.463-10%488832470.400+22%534860919.834+11%578847567.165+3%675289924.310-12%
Usd Price Per Share4.430+30%3.0903.425-10%2.550+21%2.789+11%3.019+2%3.522-12%
Usd Profit--2523000.000-13563000.000+638%-19271750.000+864%-17010833.333+774%-17310700.000+786%-27194200.000+1178%
Usd Revenue--10739000.0003854000.000+179%2515250.000+327%4084333.333+163%4536550.000+137%3365850.000+219%
Usd Total Gains Per Share--0.018-0.052+383%-0.016+187%-0.031+267%0.018+3%-0.054+394%
 EOD+5 -3MRQTTM+21 -16YOY+28 -103Y+28 -105Y+25 -1510Y+19 -21

3.3 Fundamental Score

Let's check the fundamental score of Arbutus Biopharma Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1584.456
Price to Book Ratio (EOD)Between0-110.272
Net Profit Margin (MRQ)Greater than00.235
Operating Margin (MRQ)Greater than00.238
Quick Ratio (MRQ)Greater than131.838
Current Ratio (MRQ)Greater than120.533
Debt to Asset Ratio (MRQ)Less than10.196
Debt to Equity Ratio (MRQ)Less than10.245
Return on Equity (MRQ)Greater than0.150.030
Return on Assets (MRQ)Greater than0.050.024
Total6/10 (60.0%)

3.4 Technical Score

Let's check the technical score of Arbutus Biopharma Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5063.811
Ma 20Greater thanMa 504.028
Ma 50Greater thanMa 1003.587
Ma 100Greater thanMa 2003.465
OpenGreater thanClose4.382
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Fundamental data was last updated by Penke on 2025-08-23 09:11:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Arbutus Biopharma Corp earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Arbutus Biopharma Corp to the Biotechnology industry mean.
  • A Net Profit Margin of 23.5% means that $0.23 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Arbutus Biopharma Corp:

  • The MRQ is 23.5%. The company is making a huge profit. +2
  • The TTM is -908.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ23.5%TTM-908.9%+932.4%
TTM-908.9%YOY-911.4%+2.5%
TTM-908.9%5Y-677.8%-231.1%
5Y-677.8%10Y566.7%-1,244.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ23.5%-85.5%+109.0%
TTM-908.9%-171.0%-737.9%
YOY-911.4%-210.0%-701.4%
3Y-711.5%-289.9%-421.6%
5Y-677.8%-381.1%-296.7%
10Y566.7%-520.3%+1,087.0%
4.3.1.2. Return on Assets

Shows how efficient Arbutus Biopharma Corp is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Arbutus Biopharma Corp to the Biotechnology industry mean.
  • 2.4% Return on Assets means that Arbutus Biopharma Corp generated $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Arbutus Biopharma Corp:

  • The MRQ is 2.4%. Using its assets, the company is less efficient in making profit.
  • The TTM is -10.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ2.4%TTM-10.5%+13.0%
TTM-10.5%YOY-12.6%+2.1%
TTM-10.5%5Y-10.9%+0.4%
5Y-10.9%10Y-13.4%+2.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4%-11.9%+14.3%
TTM-10.5%-11.9%+1.4%
YOY-12.6%-11.2%-1.4%
3Y-10.9%-12.0%+1.1%
5Y-10.9%-11.7%+0.8%
10Y-13.4%-13.8%+0.4%
4.3.1.3. Return on Equity

Shows how efficient Arbutus Biopharma Corp is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Arbutus Biopharma Corp to the Biotechnology industry mean.
  • 3.0% Return on Equity means Arbutus Biopharma Corp generated $0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Arbutus Biopharma Corp:

  • The MRQ is 3.0%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -14.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ3.0%TTM-14.8%+17.9%
TTM-14.8%YOY-16.7%+1.9%
TTM-14.8%5Y-14.7%-0.1%
5Y-14.7%10Y-18.0%+3.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0%-14.2%+17.2%
TTM-14.8%-15.2%+0.4%
YOY-16.7%-15.3%-1.4%
3Y-14.8%-16.9%+2.1%
5Y-14.7%-17.5%+2.8%
10Y-18.0%-19.6%+1.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Arbutus Biopharma Corp.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Arbutus Biopharma Corp is operating .

  • Measures how much profit Arbutus Biopharma Corp makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Arbutus Biopharma Corp to the Biotechnology industry mean.
  • An Operating Margin of 23.8% means the company generated $0.24  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Arbutus Biopharma Corp:

  • The MRQ is 23.8%. The company is operating efficient. +1
  • The TTM is -907.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ23.8%TTM-907.4%+931.2%
TTM-907.4%YOY-909.4%+2.0%
TTM-907.4%5Y-663.4%-244.0%
5Y-663.4%10Y-1,137.4%+474.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ23.8%-154.1%+177.9%
TTM-907.4%-280.2%-627.2%
YOY-909.4%-268.7%-640.7%
3Y-708.9%-281.5%-427.4%
5Y-663.4%-350.8%-312.6%
10Y-1,137.4%-530.7%-606.7%
4.3.2.2. Operating Ratio

Measures how efficient Arbutus Biopharma Corp is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.82 means that the operating costs are $0.82 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Arbutus Biopharma Corp:

  • The MRQ is 0.822. The company is less efficient in keeping operating costs low.
  • The TTM is 12.136. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.822TTM12.136-11.314
TTM12.136YOY13.250-1.114
TTM12.1365Y10.226+1.910
5Y10.22610Y18.619-8.392
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8221.952-1.130
TTM12.1362.974+9.162
YOY13.2503.047+10.203
3Y9.8953.835+6.060
5Y10.2264.924+5.302
10Y18.6196.864+11.755
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Arbutus Biopharma Corp.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Arbutus Biopharma Corp is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 20.53 means the company has $20.53 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Arbutus Biopharma Corp:

  • The MRQ is 20.533. The company is very able to pay all its short-term debts. +2
  • The TTM is 10.428. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ20.533TTM10.428+10.105
TTM10.428YOY6.367+4.061
TTM10.4285Y9.310+1.119
5Y9.31010Y11.412-2.102
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ20.5333.480+17.053
TTM10.4283.790+6.638
YOY6.3674.104+2.263
3Y7.4554.609+2.846
5Y9.3105.764+3.546
10Y11.4126.154+5.258
4.4.3.2. Quick Ratio

Measures if Arbutus Biopharma Corp is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Arbutus Biopharma Corp to the Biotechnology industry mean.
  • A Quick Ratio of 31.84 means the company can pay off $31.84 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Arbutus Biopharma Corp:

  • The MRQ is 31.838. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 16.758. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ31.838TTM16.758+15.080
TTM16.758YOY10.509+6.249
TTM16.7585Y13.981+2.777
5Y13.98110Y17.343-3.362
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ31.8382.938+28.900
TTM16.7583.291+13.467
YOY10.5093.928+6.581
3Y12.3084.393+7.915
5Y13.9815.837+8.144
10Y17.3436.549+10.794
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Arbutus Biopharma Corp.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Arbutus Biopharma Corp assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Arbutus Biopharma Corp to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.20 means that Arbutus Biopharma Corp assets are financed with 19.6% credit (debt) and the remaining percentage (100% - 19.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Arbutus Biopharma Corp:

  • The MRQ is 0.196. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.255. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.196TTM0.255-0.058
TTM0.255YOY0.246+0.008
TTM0.2555Y0.252+0.003
5Y0.25210Y0.238+0.014
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1960.339-0.143
TTM0.2550.359-0.104
YOY0.2460.334-0.088
3Y0.2560.341-0.085
5Y0.2520.349-0.097
10Y0.2380.379-0.141
4.5.4.2. Debt to Equity Ratio

Measures if Arbutus Biopharma Corp is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Arbutus Biopharma Corp to the Biotechnology industry mean.
  • A Debt to Equity ratio of 24.5% means that company has $0.24 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Arbutus Biopharma Corp:

  • The MRQ is 0.245. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.347. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.245TTM0.347-0.103
TTM0.347YOY0.327+0.020
TTM0.3475Y0.340+0.007
5Y0.34010Y0.320+0.020
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2450.391-0.146
TTM0.3470.436-0.089
YOY0.3270.436-0.109
3Y0.3470.461-0.114
5Y0.3400.461-0.121
10Y0.3200.514-0.194
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Arbutus Biopharma Corp generates.

  • Above 15 is considered overpriced but always compare Arbutus Biopharma Corp to the Biotechnology industry mean.
  • A PE ratio of 58.91 means the investor is paying $58.91 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Arbutus Biopharma Corp:

  • The EOD is 84.456. Based on the earnings, the company is expensive. -2
  • The MRQ is 58.910. Based on the earnings, the company is expensive. -2
  • The TTM is 7.557. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD84.456MRQ58.910+25.547
MRQ58.910TTM7.557+51.353
TTM7.557YOY-6.360+13.917
TTM7.5575Y-4.297+11.854
5Y-4.29710Y9.231-13.528
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD84.456-2.539+86.995
MRQ58.910-2.361+61.271
TTM7.557-2.657+10.214
YOY-6.360-3.749-2.611
3Y-1.738-3.883+2.145
5Y-4.297-6.353+2.056
10Y9.231-7.102+16.333
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Arbutus Biopharma Corp:

  • The EOD is -13.530. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -9.437. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -11.473. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-13.530MRQ-9.437-4.093
MRQ-9.437TTM-11.473+2.036
TTM-11.473YOY-7.152-4.321
TTM-11.4735Y-8.029-3.444
5Y-8.02910Y-12.435+4.406
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-13.530-3.411-10.119
MRQ-9.437-2.951-6.486
TTM-11.473-3.614-7.859
YOY-7.152-4.421-2.731
3Y-8.049-5.258-2.791
5Y-8.029-8.587+0.558
10Y-12.435-9.639-2.796
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Arbutus Biopharma Corp is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 7.16 means the investor is paying $7.16 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Arbutus Biopharma Corp:

  • The EOD is 10.272. Based on the equity, the company is expensive. -2
  • The MRQ is 7.165. Based on the equity, the company is overpriced. -1
  • The TTM is 7.240. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD10.272MRQ7.165+3.107
MRQ7.165TTM7.240-0.075
TTM7.240YOY4.233+3.007
TTM7.2405Y5.037+2.203
5Y5.03710Y4.451+0.586
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD10.2722.206+8.066
MRQ7.1652.027+5.138
TTM7.2402.194+5.046
YOY4.2332.425+1.808
3Y4.9152.571+2.344
5Y5.0373.805+1.232
10Y4.4514.462-0.011
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Arbutus Biopharma Corp.

4.8.1. Institutions holding Arbutus Biopharma Corp

Institutions are holding 62.697% of the shares of Arbutus Biopharma Corp.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Morgan Stanley - Brokerage Accounts12.4150.00592379238912054715.337
2025-03-31Whitefort Capital Management, LP.6.944221.85313307967660510.4988
2025-03-31BlackRock Inc6.66170.000912766622-170832-1.3204
2025-03-31Two Seas Capital LP4.93941.040894659567250008.2943
2025-06-30Vanguard Group Inc4.74070.000590850861312631.466
2025-03-31State Street Corp2.27690.00064363507-663122-13.1922
2025-03-31Geode Capital Management, LLC1.84780.0013541145590091.6946
2025-06-30Goldman Sachs Group Inc1.58620.0013303978396383546.4287
2025-03-31Woodline Partners LP1.38580.060326557381684110173.3287
2025-03-31FourSixThree Capital LP1.27862.3568245042124504210
2025-03-31BlackBarn Capital Partners LP1.2220.5198234187100
2025-03-31ADAR1 Capital Management LLC0.98051.2175187911432431220.8587
2025-03-31Rubric Capital Management LP0.87720.1051168109000
2025-03-31Adage Capital Partners Gp LLC0.82230.01021575941-75000-4.5429
2025-03-31Advisor Group Holdings, Inc.0.70180.01051344906-2418-0.1795
2025-03-31Northern Trust Corp0.66980.00071283601-47082-3.5382
2025-06-30Charles Schwab Investment Management Inc0.65430.00071253829317642.5992
2025-03-31Hudson Bay Capital Management LP0.65010.0134124590013340011.991
2025-03-31FourWorld Capital Management LLC0.64012.7525122671000
2025-06-30UBS Asset Mgmt Americas Inc0.55980.00071072744957794833.2266
Total 51.854229.952299374320+7773976+7.8%

4.9.2. Funds holding Arbutus Biopharma Corp

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30Vanguard Total Stock Mkt Idx Inv2.54170.0008487101500
2025-03-31Morgan Stanley Insight2.19041.22364197659-47114-1.1099
2025-03-31Morgan Stanley Insight I2.19041.2284197659-47114-1.1099
2025-07-31iShares Russell 2000 ETF1.85280.01923550660-67515-1.866
2025-03-31MS INVF Global Insight Z1.30641.4841250363900
2025-06-30Vanguard Institutional Extnd Mkt Idx Tr1.24390.00642383793124730.526
2025-03-31Morgan Stanley Inst Inception I1.10992.41692126968-157499-6.8943
2025-03-31Morgan Stanley Inception1.10992.4182126968-157499-6.8943
2025-06-30EQ/Morgan Stanley Small Cap Growth K0.8731.1849167300618810.1126
2025-05-31Fidelity Small Cap Index0.77430.02148389656320.381
2025-07-31abrdn Life Sciences Investors0.68021.0008130349132096432.6672
2025-07-31iShares Russell 2000 Growth ETF0.65010.035124576900
2025-07-31SPDR® S&P Biotech ETF0.56230.07351077622322273.0828
2025-07-31iShares Biotechnology ETF0.48080.055692140378750.862
2025-07-31State St Russell Sm/Mid Cp® Indx SL Cl I0.4740.006890841900
2025-06-30Fidelity Extended Market Index0.42560.0064815696-2129-0.2603
2025-06-30Vanguard Russell 2000 ETF0.39440.0177755793171212.3178
2025-07-31Schwab US Small-Cap ETF™0.37150.0133711964-364-0.0511
2025-04-30UBS (Lux) EF Biotech (USD) P-acc0.35860.662668728025770059.9888
2025-03-31MS INVF Global Endurance Z USD Acc0.25455.1713487788254491109.0846
Total 19.844717.044938030488+431130+1.1%

5.3. Insider Transactions

Insiders are holding 21.874% of the shares of Arbutus Biopharma Corp.

DateOwnerTypeAmountPricePost Transaction AmountLink
2021-02-09Michael J McelhaughSELL200005
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-06-302024-09-302024-12-312025-03-312025-06-30
Income before Tax  -19,79679-19,7177,185-12,532-11,994-24,52627,0492,523
Net Income  -19,79679-19,7177,185-12,532-11,994-24,52627,0492,523
EBIT  -19,76274-19,6887,186-12,502-11,996-24,49827,0492,551
EBITDA  -19,40654-19,3527,183-12,169-11,996-24,16526,7272,562
Operating Income  -21,372-68-21,4407,507-13,933-20,725-34,65836,5711,913
Net Income from Continuing Operations  -19,79679-19,7177,185-12,532-11,994-24,52627,0492,523



5.2. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets103,267
Total Liabilities20,291
Total Stockholder Equity82,976
 As reported
Total Liabilities 20,291
Total Stockholder Equity+ 82,976
Total Assets = 103,267

Assets

Total Assets103,267
Total Current Assets103,119
Long-term Assets148
Total Current Assets
Cash And Cash Equivalents 37,412
Short-term Investments 60,676
Net Receivables 1,125
Other Current Assets 3,906
Total Current Assets  (as reported)103,119
Total Current Assets  (calculated)103,119
+/-0
Long-term Assets
Property Plant Equipment 148
Long-term Assets  (as reported)148
Long-term Assets  (calculated)148
+/- 0

Liabilities & Shareholders' Equity

Total Current Liabilities5,022
Long-term Liabilities15,269
Total Stockholder Equity82,976
Total Current Liabilities
Short-term Debt 514
Accounts payable 1,321
Other Current Liabilities 3,187
Total Current Liabilities  (as reported)5,022
Total Current Liabilities  (calculated)5,022
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt575
Long-term Liabilities Other 14,694
Long-term Liabilities  (as reported)15,269
Long-term Liabilities  (calculated)15,269
+/-0
Total Stockholder Equity
Common Stock1,417,110
Retained Earnings -1,368,575
Accumulated Other Comprehensive Income -48,187
Other Stockholders Equity 82,628
Total Stockholder Equity (as reported)82,976
Total Stockholder Equity (calculated)82,976
+/-0
Other
Capital Stock1,417,110
Cash and Short Term Investments 98,088
Common Stock Shares Outstanding 192,400
Liabilities and Stockholders Equity 103,267
Net Debt -32,413
Net Invested Capital 82,976
Net Working Capital 98,097
Property Plant and Equipment Gross 13,463
Short Long Term Debt Total 4,999



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-31
> Total Assets 
39,916
36,988
34,568
32,689
29,298
44,756
42,887
67,603
65,897
68,830
60,437
53,271
48,903
44,376
54,715
50,721
56,436
49,575
46,969
41,069
32,869
27,416
20,983
18,422
15,645
7,834
7,991
6,033
25,769
24,955
25,870
24,834
22,211
62,193
52,152
42,342
39,712
41,648
43,452
41,947
37,047
35,365
35,215
21,019
17,408
19,053
14,862
13,704
14,695
11,632
10,292
52,600
50,496
45,909
43,379
71,716
138,522
132,068
125,059
118,178
787,064
773,800
722,631
712,291
703,254
530,861
514,730
275,919
268,140
255,075
239,845
237,161
270,026
277,014
245,418
227,905
209,216
192,570
117,277
105,535
102,614
97,625
131,104
137,080
146,240
135,376
165,596
204,485
236,877
215,836
203,801
195,419
191,224
176,823
158,641
144,401
150,290
160,043
140,441
131,707
117,010
103,267
103,267117,010131,707140,441160,043150,290144,401158,641176,823191,224195,419203,801215,836236,877204,485165,596135,376146,240137,080131,10497,625102,614105,535117,277192,570209,216227,905245,418277,014270,026237,161239,845255,075268,140275,919514,730530,861703,254712,291722,631773,800787,064118,178125,059132,068138,52271,71643,37945,90950,49652,60010,29211,63214,69513,70414,86219,05317,40821,01935,21535,36537,04741,94743,45241,64839,71242,34252,15262,19322,21124,83425,87024,95525,7696,0337,9917,83415,64518,42220,98327,41632,86941,06946,96949,57556,43650,72154,71544,37648,90353,27160,43768,83065,89767,60342,88744,75629,29832,68934,56836,98839,916
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,743
24,481
23,294
20,399
40,129
34,857
27,330
25,002
26,011
26,724
24,790
19,365
18,624
18,523
17,906
14,393
16,273
12,512
11,551
12,733
9,918
8,741
51,248
49,138
44,539
42,011
70,343
137,001
118,164
111,737
116,418
239,769
215,700
200,027
183,882
174,757
168,085
151,812
132,564
120,268
105,922
90,813
129,366
175,186
157,769
144,025
129,229
112,486
99,583
94,341
93,828
88,333
85,536
121,242
127,704
137,341
83,466
126,536
160,661
172,698
157,791
141,136
151,139
152,854
158,800
141,607
132,027
135,872
148,220
132,777
127,316
116,808
103,119
103,119116,808127,316132,777148,220135,872132,027141,607158,800152,854151,139141,136157,791172,698160,661126,53683,466137,341127,704121,24285,53688,33393,82894,34199,583112,486129,229144,025157,769175,186129,36690,813105,922120,268132,564151,812168,085174,757183,882200,027215,700239,769116,418111,737118,164137,00170,34342,01144,53949,13851,2488,7419,91812,73311,55112,51216,27314,39317,90618,52318,62419,36524,79026,72426,01125,00227,33034,85740,12920,39923,29424,48123,74300000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
2,058
0
0
0
25,634
0
0
0
20,525
0
0
0
35,550
0
0
0
24,976
0
0
0
10,440
0
0
0
4,864
23,752
21,080
21,117
21,130
19,399
29,048
26,919
21,543
23,798
11,981
12,707
23,300
18,176
17,254
15,409
12,344
9,495
10,027
8,880
8,995
8,765
6,821
5,723
47,029
43,059
38,717
35,789
68,717
134,357
85,267
78,177
72,187
232,276
207,200
181,089
166,779
144,772
42,970
26,630
23,413
29,851
24,212
15,225
54,292
12,461
10,193
21,933
36,942
83,969
78,872
90,082
31,799
26,416
45,899
96,918
52,251
79,421
30,954
77,883
109,282
81,330
47,320
24,004
30,776
40,574
27,197
17,531
26,285
43,101
62,788
31,846
36,330
37,076
37,412
37,41237,07636,33031,84662,78843,10126,28517,53127,19740,57430,77624,00447,32081,330109,28277,88330,95479,42152,25196,91845,89926,41631,79990,08278,87283,96936,94221,93310,19312,46154,29215,22524,21229,85123,41326,63042,970144,772166,779181,089207,200232,27672,18778,17785,267134,35768,71735,78938,71743,05947,0295,7236,8218,7658,9958,88010,0279,49512,34415,40917,25418,17623,30012,70711,98123,79821,54326,91929,04819,39921,13021,11721,08023,7524,86400010,44000024,97600035,55000020,52500025,6340002,058000
       Short-term Investments 
0
0
0
22,037
0
0
0
21,928
0
0
0
17,686
0
0
0
3,648
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,166
5,386
4,709
0
12,512
12,480
0
0
0
0
0
0
0
0
0
0
0
0
0
27,210
0
0
0
0
31,966
30,580
39,974
39,974
0
15,006
14,525
27,802
122,340
123,052
107,146
80,528
78,797
72,954
72,060
160,079
144,676
120,085
87,675
26,621
16,410
0
59,035
58,475
36,489
21,378
71,017
52,540
47,425
43,520
46,035
84,147
102,879
110,714
116,137
106,154
125,287
116,649
99,718
86,139
79,198
95,948
86,293
75,631
60,676
60,67675,63186,29395,94879,19886,13999,718116,649125,287106,154116,137110,714102,87984,14746,03543,52047,42552,54071,01721,37836,48958,47559,035016,41026,62187,675120,085144,676160,07972,06072,95478,79780,528107,146123,052122,34027,80214,52515,006039,97439,97430,58031,966000027,210000000000000012,48012,51204,7095,3868,166000000000000000003,64800017,68600021,92800022,037000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,167
2,573
1,838
687
2,544
2,213
520
1,153
1,378
1,254
1,273
1,009
1,183
2,704
3,722
3,832
5,011
2,519
1,044
2,776
2,139
2,090
3,459
4,895
4,719
5,110
369
1,972
539
2,246
2,527
6,238
6,300
2,698
1,382
714
732
671
694
8,314
1,330
1,134
870
1,189
1,664
880
1,431
1,214
1,531
2,488
1,204
1,072
1,108
1,075
1,312
1,265
1,298
1,667
899
1,313
1,970
1,835
1,352
2,664
2,614
2,171
1,776
2,139
1,767
1,608
2,409
1,182
1,125
1,1251,1822,4091,6081,7672,1391,7762,1712,6142,6641,3521,8351,9701,3138991,6671,2981,2651,3121,0751,1081,0721,2042,4881,5311,2141,4318801,6641,1898701,1341,3308,3146946717327141,3822,6986,3006,2382,5272,2465391,9723695,1104,7194,8953,4592,0902,1392,7761,0442,5195,0113,8323,7222,7041,1831,0091,2731,2541,3781,1535202,2132,5446871,8382,5731,16700000000000000000000000000000
       Inventory 
0
0
0
209
197
216
0
0
0
0
0
0
0
0
0
0
0
0
239
0
0
0
0
0
0
0
0
0
200
1,370
649
215
197
160
179
143
0
0
108
0
0
0
0
151
858
218
0
0
0
0
0
0
-2,249
-1,959
-17
872
260
192
0
1,192
-340
0
780
1,068
1,341
1,915
1,331
1,183
1,447
1,455
1,372
2,016
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-2,874
-3,462
-2,614
-5,256
0
0
-6,234
0
0
0
0
0000-6,23400-5,256-2,614-3,462-2,87400000000000000000002,0161,3721,4551,4471,1831,3311,9151,3411,0687800-3401,1920192260872-17-1,959-2,2490000002188581510000108001431791601972156491,370200000000000239000000000000216197209000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,212
1,389
1,540
1,812
22,063
17,295
15,012
14,710
15,637
16,728
17,157
17,683
16,741
16,693
3,113
3,015
2,780
2,351
2,152
1,962
1,714
1,551
1,352
1,357
1,370
1,368
1,373
1,521
13,904
13,322
1,760
547,295
558,100
522,604
528,409
528,497
362,776
362,918
143,355
147,872
149,153
149,032
107,795
94,840
119,245
101,393
98,676
96,730
92,987
22,936
11,707
14,281
12,089
9,862
9,376
8,899
51,910
39,060
43,824
64,179
58,045
62,665
44,280
38,370
18,023
17,034
12,374
14,418
11,823
7,664
4,391
202
148
1482024,3917,66411,82314,41812,37417,03418,02338,37044,28062,66558,04564,17943,82439,06051,9108,8999,3769,86212,08914,28111,70722,93692,98796,73098,676101,393119,24594,840107,795149,032149,153147,872143,355362,918362,776528,497528,409522,604558,100547,2951,76013,32213,9041,5211,3731,3681,3701,3571,3521,5511,7141,9622,1522,3512,7803,0153,11316,69316,74117,68317,15716,72815,63714,71015,01217,29522,0631,8121,5401,3891,21200000000000000000000000000000
       Property Plant Equipment 
2,748
2,564
2,459
2,445
2,386
2,629
2,583
2,790
3,124
3,597
3,688
3,748
3,758
3,996
3,810
4,096
3,969
4,080
4,115
3,430
3,152
1,532
1,131
949
906
687
574
500
748
1,212
1,389
1,540
1,554
2,356
2,262
2,145
2,509
2,586
2,790
2,686
3,126
3,009
2,936
3,113
3,015
2,780
2,351
2,152
1,962
1,714
1,551
1,352
1,357
1,370
1,368
1,373
1,521
1,676
1,613
1,760
1,778
2,000
2,325
3,183
3,242
3,944
4,086
6,945
11,462
12,743
12,622
12,183
11,829
10,681
10,421
10,145
12,748
12,303
11,967
11,414
10,833
10,316
9,753
9,332
8,899
9,004
8,526
8,075
7,671
7,415
7,062
6,814
6,518
6,955
6,535
6,090
5,741
5,296
4,700
4,357
168
148
1481684,3574,7005,2965,7416,0906,5356,9556,5186,8147,0627,4157,6718,0758,5269,0048,8999,3329,75310,31610,83311,41411,96712,30312,74810,14510,42110,68111,82912,18312,62212,74311,4626,9454,0863,9443,2423,1832,3252,0001,7781,7601,6131,6761,5211,3731,3681,3701,3571,3521,5511,7141,9622,1522,3512,7803,0153,1132,9363,0093,1262,6862,7902,5862,5092,1452,2622,3561,5541,5401,3891,2127485005746879069491,1311,5323,1523,4304,1154,0803,9694,0963,8103,9963,7583,7483,6883,5973,1242,7902,5832,6292,3862,4452,4592,5642,748
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,823
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
155,865
156,100
156,637
162,514
162,514
162,514
162,514
24,364
24,364
24,364
24,364
24,364
24,364
22,471
22,471
22,471
22,471
22,471
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000022,47122,47122,47122,47122,47124,36424,36424,36424,36424,36424,364162,514162,514162,514162,514156,637156,100155,865000000000000000000000000003,823000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,228
11,709
0
0
0
10,041
10,070
0
0
0
0
0
0
0
0
0
27,446
24,665
22,224
17,675
14,377
10,969
0
3,215
1,600
0
0
0
42,906
30,534
35,688
56,318
50,450
55,436
37,363
31,790
11,057
10,496
6,284
8,677
6,527
2,964
0
0
0
0002,9646,5278,6776,28410,49611,05731,79037,36355,43650,45056,31835,68830,53442,9060001,6003,215010,96914,37717,67522,22424,66527,44600000000010,07010,04100011,70912,228000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
11,669
11,124
9,506
8,459
7,848
7,231
5,884
4,764
7,476
9,530
9,735
7,189
6,953
6,663
6,816
6,594
6,376
0
0
0
0
0
0
0
0
15,885
15,033
12,867
12,200
13,051
13,937
14,471
14,557
13,732
13,757
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
389,652
390,000
353,601
352,642
352,642
196,318
196,318
99,445
99,445
99,445
99,445
58,647
58,647
58,647
43,836
43,836
43,836
43,836
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000043,83643,83643,83643,83658,64758,64758,64799,44599,44599,44599,445196,318196,318352,642352,642353,601390,000389,6520000000000000000013,75713,73214,55714,47113,93713,05112,20012,86715,03315,885000000006,3766,5946,8166,6636,9537,1899,7359,5307,4764,7645,8847,2317,8488,4599,50611,12411,66900000000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
258
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,325
341,000
0
0
0
12,601
12,601
12,601
12,601
12,601
12,601
27,446
24,665
22,224
3,081
14,377
2,817
293
233
173
109
44
44
42,906
0
61
190
180
167
103
62
11
3
0
0
0
0
34
34
0
0343400003116210316718019061042,90644441091732332932,81714,3773,08122,22424,66527,44612,60112,60112,60112,60112,60112,601000341,0002,3250000000000000000000000000000025800000000000000000000000000000000
> Total Liabilities 
2,074
1,904
1,917
2,508
2,533
3,466
4,064
6,117
6,139
6,065
6,530
7,876
6,435
6,188
4,967
7,346
16,773
14,097
14,274
51,558
36,509
40,118
35,986
36,842
37,175
11,305
8,051
5,878
11,973
9,882
7,955
6,464
4,929
7,932
5,513
4,053
4,364
5,068
6,336
6,510
4,628
7,930
9,678
10,288
9,460
10,629
8,212
8,498
9,309
8,092
9,978
11,678
12,628
11,892
13,543
12,522
33,039
26,923
29,563
30,143
193,373
185,300
168,824
164,612
165,177
99,537
98,105
72,914
79,042
79,289
72,454
54,688
37,608
38,942
30,146
27,671
28,007
28,104
33,640
32,791
29,358
32,114
33,759
35,114
32,091
34,547
35,456
35,046
71,032
62,694
58,284
58,567
47,309
42,130
39,304
38,383
35,653
37,589
33,551
34,341
37,853
20,291
20,29137,85334,34133,55137,58935,65338,38339,30442,13047,30958,56758,28462,69471,03235,04635,45634,54732,09135,11433,75932,11429,35832,79133,64028,10428,00727,67130,14638,94237,60854,68872,45479,28979,04272,91498,10599,537165,177164,612168,824185,300193,37330,14329,56326,92333,03912,52213,54311,89212,62811,6789,9788,0929,3098,4988,21210,6299,46010,2889,6787,9304,6286,5106,3365,0684,3644,0535,5137,9324,9296,4647,9559,88211,9735,8788,05111,30537,17536,84235,98640,11836,50951,55814,27414,09716,7737,3464,9676,1886,4357,8766,5306,0656,1396,1174,0643,4662,5332,5081,9171,9042,074
   > Total Current Liabilities 
1,560
1,419
1,461
1,915
1,560
2,702
1,325
2,584
3,183
3,448
3,168
4,803
3,492
3,451
2,629
4,533
5,953
3,950
4,504
10,877
3,146
6,833
1,965
2,201
1,586
11,136
7,935
5,813
8,940
7,688
6,782
6,464
4,929
7,932
5,447
4,053
4,364
5,068
6,336
6,510
4,628
7,930
9,678
8,133
7,285
8,475
6,406
6,842
7,780
6,823
8,934
10,955
12,319
11,892
13,543
12,522
23,039
16,413
19,488
20,206
24,875
10,500
13,831
10,578
11,112
10,084
8,392
10,585
10,871
11,881
8,235
14,627
10,396
11,541
12,668
11,239
8,823
8,799
8,817
7,828
4,031
6,327
7,608
9,541
6,693
8,841
10,113
11,221
32,409
29,824
27,506
32,857
25,154
24,529
22,324
22,487
20,296
22,595
18,923
15,618
19,431
5,022
5,02219,43115,61818,92322,59520,29622,48722,32424,52925,15432,85727,50629,82432,40911,22110,1138,8416,6939,5417,6086,3274,0317,8288,8178,7998,82311,23912,66811,54110,39614,6278,23511,88110,87110,5858,39210,08411,11210,57813,83110,50024,87520,20619,48816,41323,03912,52213,54311,89212,31910,9558,9346,8237,7806,8426,4068,4757,2858,1339,6787,9304,6286,5106,3365,0684,3644,0535,4477,9324,9296,4646,7827,6888,9405,8137,93511,1361,5862,2011,9656,8333,14610,8774,5043,9505,9534,5332,6293,4513,4924,8033,1683,4483,1832,5841,3252,7021,5601,9151,4611,4191,560
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
88
103
153
52
31
9
2,934
0
0
0
0
0
0
0
0
0
2,917
2,806
0
1,785
1,729
1,812
2,990
3,251
3,456
3,501
2,463
2,453
2,002
2,515
7,284
6,777
1,507
4,603
6,217
3,718
6,009
5,061
6,695
5,814
4,906
4,112
8,659
6,545
5,267
6,206
0
1,198
752
658
680
816
728
756
780
864
714
772
766
878
754
720
744
892
794
824
850
1,004
906
468
483
563
514
5145634834689061,0048508247948927447207548787667727148647807567288166806587521,19806,2065,2676,5458,6594,1124,9065,8146,6955,0616,0093,7186,2174,6031,5076,7777,2842,5152,0022,4532,4633,5013,4563,2512,9901,8121,7291,78502,8062,9170000000002,934931521531038800000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,001
12,001
12,001
12,001
12,001
0
0
0
0
599
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000599000012,00112,00112,00112,00112,0010000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
1,483
1,344
1,387
1,845
1,508
2,647
1,272
2,465
2,737
2,936
2,687
4,335
2,996
2,923
2,101
3,729
2,381
1,413
2,001
929
370
295
74
237
240
168
286
314
2,116
1,162
136
314
153
5,197
4,075
509
3,616
3,161
3,487
1,997
3,375
3,006
4,277
3,044
2,716
1,877
789
1,258
1,288
1,178
1,269
806
1,267
1,475
777
1,217
2,141
1,778
3,389
2,044
7,242
2,802
2,898
2,610
3,993
1,744
2,071
3,215
1,614
3,368
2,291
1,987
943
3,208
3,075
3,192
2,344
685
1,400
2,398
519
1,182
852
2,994
355
2,063
1,042
3,174
1,194
12,474
872
3,520
2,455
1,044
2,260
3,223
3,743
2,652
2,315
2,316
2,240
1,321
1,3212,2402,3162,3152,6523,7433,2232,2601,0442,4553,52087212,4741,1943,1741,0422,0633552,9948521,1825192,3981,4006852,3443,1923,0753,2089431,9872,2913,3681,6143,2152,0711,7443,9932,6102,8982,8027,2422,0443,3891,7782,1411,2177771,4751,2678061,2691,1781,2881,2587891,8772,7163,0444,2773,0063,3751,9973,4873,1613,6165094,0755,1971533141361,1622,116314286168240237742953709292,0011,4132,3813,7292,1012,9232,9964,3352,6872,9362,7372,4651,2722,6471,5081,8451,3871,3441,483
       Other Current Liabilities 
77
75
74
15
0
0
0
0
328
346
330
333
357
389
387
388
2,981
1,820
1,749
9,172
1,646
4,914
1,470
1,542
894
10,498
7,564
5,416
6,741
61
769
1,345
1,368
0
0
3,167
3,611
3,167
3,488
3,403
3,361
3,035
4,265
6,151
4,828
3,526
3,108
5,584
3,356
2,646
4,526
7,006
6,704
6,632
8,487
11,305
15,277
8,592
11,222
18,162
12,400
3,600
6,098
7,968
6,195
8,340
6,306
660
819
983
1,817
1,239
7,733
7,359
8,944
8,047
5,281
7,362
6,759
4,750
2,696
4,417
6,000
5,767
5,474
6,064
8,299
7,281
12,726
12,097
19,248
20,544
12,026
12,037
11,623
9,897
6,613
13,528
7,305
5,248
12,109
3,187
3,18712,1095,2487,30513,5286,6139,89711,62312,03712,02620,54419,24812,09712,7267,2818,2996,0645,4745,7676,0004,4172,6964,7506,7597,3625,2818,0478,9447,3597,7331,2391,8179838196606,3068,3406,1957,9686,0983,60012,40018,16211,2228,59215,27711,3058,4876,6326,7047,0064,5262,6463,3565,5843,1083,5264,8286,1514,2653,0353,3613,4033,4883,1673,6113,167001,3681,345769616,7415,4167,56410,4988941,5421,4704,9141,6469,1721,7491,8202,981388387389357333330346328000015747577
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,194
1,173
0
0
0
65
0
0
0
0
0
0
0
0
2,155
2,175
2,154
1,806
1,656
1,529
1,269
1,044
723
310
0
0
10,000
10,000
10,510
10,075
9,937
168,498
174,800
154,993
154,034
154,065
89,453
89,713
62,329
68,171
67,408
64,219
40,061
27,212
27,401
17,478
16,432
19,184
19,305
24,823
24,963
25,327
25,787
26,151
25,573
25,398
25,706
25,343
23,825
38,623
32,870
30,778
25,710
22,155
17,601
16,980
15,896
15,357
14,994
14,628
18,723
18,422
15,269
15,26918,42218,72314,62814,99415,35715,89616,98017,60122,15525,71030,77832,87038,62323,82525,34325,70625,39825,57326,15125,78725,32724,96324,82319,30519,18416,43217,47827,40127,21240,06164,21967,40868,17162,32989,71389,453154,065154,034154,993174,800168,4989,93710,07510,51010,00010,000003107231,0441,2691,5291,6561,8062,1542,1752,15500000000650001,1732,19400000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,001
12,001
12,001
12,001
12,001
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000012,00112,00112,00112,00112,0010000000000000000000000000000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-88
-103
-153
-52
-31
-9
-2,934
0
0
0
0
0
0
0
0
0
-2,917
-2,806
0
-1,785
-1,729
-1,812
-2,990
-3,251
-3,456
-3,501
-2,463
-2,453
-2,002
-2,515
-7,284
-6,777
-1,507
-4,603
-6,217
-3,718
-6,009
-5,061
-6,695
-5,814
-4,906
-4,112
-8,659
-6,545
-5,267
-6,206
0
2,673
2,887
2,814
2,678
2,479
2,503
2,355
2,203
2,045
2,118
1,969
1,848
1,661
1,711
1,595
1,443
1,225
1,249
1,085
918
679
691
978
806
626
575
5756268069786916799181,0851,2491,2251,4431,5951,7111,6611,8481,9692,1182,0452,2032,3552,5032,4792,6782,8142,8872,6730-6,206-5,267-6,545-8,659-4,112-4,906-5,814-6,695-5,061-6,009-3,718-6,217-4,603-1,507-6,777-7,284-2,515-2,002-2,453-2,463-3,501-3,456-3,251-2,990-1,812-1,729-1,7850-2,806-2,917000000000-2,934-9-31-52-153-103-8800000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,736
5,136
6,665
7,497
7,741
7,993
8,253
9,065
10,124
10,014
10,211
10,424
9,576
9,769
4,161
3,126
6,523
6,644
24,823
24,963
25,327
25,787
26,151
19,554
25,398
23,231
25,343
16,296
23,038
22,028
20,193
19,711
18,859
17,601
15,483
14,553
14,176
13,850
13,650
15,054
14,933
14,694
14,69414,93315,05413,65013,85014,17614,55315,48317,60118,85919,71120,19322,02823,03816,29625,34323,23125,39819,55426,15125,78725,32724,96324,8236,6446,5233,1264,1619,7699,57610,42410,21110,01410,1249,0658,2537,9937,7417,4976,6655,1364,736000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,000
10,510
10,075
9,937
163,762
156,007
148,328
146,537
146,324
81,460
81,460
41,263
46,046
45,393
42,007
17,636
17,636
17,632
13,317
13,306
12,661
12,661
0
0
0
0
0
0
0
0
0
0
15,585
10,842
10,585
0
3,296
0
0
0
0
0
0
0
0
0
0000000003,296010,58510,84215,585000000000012,66112,66113,30613,31717,63217,63617,63642,00745,39346,04641,26381,46081,460146,324146,537148,328156,007163,7629,93710,07510,51010,00000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
37,841
35,084
32,651
30,182
26,639
41,222
38,823
61,486
59,758
62,765
53,907
45,395
42,468
38,188
49,748
43,375
39,663
35,479
32,696
0
0
0
0
0
0
0
0
155
13,797
15,073
17,915
18,370
17,282
54,261
46,639
38,289
35,348
36,580
37,116
35,437
32,420
27,435
25,538
10,731
7,948
8,425
6,651
5,206
5,386
3,540
314
40,923
37,867
34,017
29,836
59,193
105,483
105,145
95,496
88,035
593,691
588,500
553,807
547,679
538,077
431,324
416,625
203,005
189,098
175,786
167,391
182,473
232,418
238,072
215,272
200,234
181,209
164,466
83,637
72,744
73,256
65,511
97,345
101,966
114,149
100,829
130,140
169,439
165,845
153,142
145,517
136,852
143,915
134,693
119,337
106,018
114,637
122,454
106,890
97,366
79,157
82,976
82,97679,15797,366106,890122,454114,637106,018119,337134,693143,915136,852145,517153,142165,845169,439130,140100,829114,149101,96697,34565,51173,25672,74483,637164,466181,209200,234215,272238,072232,418182,473167,391175,786189,098203,005416,625431,324538,077547,679553,807588,500593,69188,03595,496105,145105,48359,19329,83634,01737,86740,9233143,5405,3865,2066,6518,4257,94810,73125,53827,43532,42035,43737,11636,58035,34838,28946,63954,26117,28218,37017,91515,07313,7971550000000032,69635,47939,66343,37549,74838,18842,46845,39553,90762,76559,75861,48638,82341,22226,63930,18232,65135,08437,841
   Common Stock
70,186
68,856
67,745
68,558
64,729
72,709
70,049
94,760
94,528
99,680
95,239
96,173
103,237
112,587
131,037
138,086
137,047
135,144
142,808
149,824
149,043
147,073
154,937
154,578
154,274
161,330
161,547
154,591
168,862
184,911
197,016
197,230
190,349
224,671
215,512
188,537
181,929
197,294
214,568
218,087
225,947
215,543
222,998
10,333,000
10,333,000
242,267
222,360
10,333,000
238,749
232,623
240,393
239,483
234,535
227,044
232,410
216,702
283,640
284,790
288,355
290,004
814,441
821,660
828,578
834,240
840,475
861,148
864,375
867,393
870,847
873,841
876,049
876,108
876,288
878,191
878,805
879,405
882,143
884,623
884,623
898,535
911,099
916,066
965,369
985,939
1,013,118
1,017,416
1,065,710
1,286,636
1,298,212
1,298,409
1,307,654
1,318,737
1,339,453
1,344,195
1,346,015
1,349,821
1,377,315
1,403,334
1,407,595
1,410,025
0
1,417,110
1,417,11001,410,0251,407,5951,403,3341,377,3151,349,8211,346,0151,344,1951,339,4531,318,7371,307,6541,298,4091,298,2121,286,6361,065,7101,017,4161,013,118985,939965,369916,066911,099898,535884,623884,623882,143879,405878,805878,191876,288876,108876,049873,841870,847867,393864,375861,148840,475834,240828,578821,660814,441290,004288,355284,790283,640216,702232,410227,044234,535239,483240,393232,623238,74910,333,000222,360242,26710,333,00010,333,000222,998215,543225,947218,087214,568197,294181,929188,537215,512224,671190,349197,230197,016184,911168,862154,591161,547161,330154,274154,578154,937147,073149,043149,824142,808135,144137,047138,086131,037112,587103,23796,17395,23999,68094,52894,76070,04972,70964,72968,55867,74568,85670,186
   Retained Earnings Total Equity00000000-1,237,236-1,220,142-1,203,803-1,181,871-1,164,304-1,150,112-1,134,347-1,112,452-1,088,207-1,065,554-1,045,961-1,025,796-1,004,014-986,932-970,093-942,559-857,264-831,187-805,221-784,325-757,285-757,835-738,070-699,631-688,031-669,776-651,149-432,454-412,859-282,859-266,985-261,721-232,739-217,853-205,864-199,696-191,092-185,01100000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income -48,187-48,166-48,135-48,090-48,308-48,371-48,421-48,884-49,468-49,634-50,488-51,004-50,097-49,406-48,335-48,187-48,199-48,168-48,171-48,127-48,099-47,977-48,229-48,217-48,244-48,192-48,170-48,197-48,185-48,185-48,185-49,782-49,782-49,782-49,782-49,782-49,782-49,782-49,782-41,588-28,264-31,487-22,313-19,035-14,208-17,983-15,825-11,882-11,504-11,742-13,000-17,442-16,669-16,766-16,148-15,695-16,554-16,251-15,553000-11,928000-11,578-10,312-10,725-10,60500000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24,837
25,655
25,872
26,208
28,590
27,844
28,538
30,206
30,243
32,817
34,486
36,543
37,809
39,758
40,755
42,840
43,769
44,429
45,500
48,084
49,594
53,738
55,385
55,246
56,803
58,300
59,614
60,751
62,133
63,933
64,096
65,485
67,151
69,134
70,738
72,406
74,238
77,202
0
0
0
0
0
0
0
0
0000000077,20274,23872,40670,73869,13467,15165,48564,09663,93362,13360,75159,61458,30056,80355,24655,38553,73849,59448,08445,50044,42943,76942,84040,75539,75837,80936,54334,48632,81730,24330,20628,53827,84428,59026,20825,87225,65524,83700000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
202,665
217,540
218,134
220,503
264,535
244,187
212,559
204,954
222,991
242,227
273,223
254,383
246,086
251,515
275,155
283,491
272,271
270,018
10,773,973
267,995
279,702
49,198
-13,521,428
30,980
29,701
30,359
25,343
24,837
25,655
25,872
26,208
28,590
27,844
28,538
30,206
30,243
32,817
34,486
36,543
37,809
39,758
40,755
42,840
43,769
44,429
45,500
48,084
49,594
53,738
55,385
55,246
56,803
58,300
59,614
60,751
62,133
63,933
64,096
65,485
67,151
69,134
70,738
72,406
74,238
77,202
79,546
81,270
80,220
81,751
81,425
82,048
127,323
82,628
82,628127,32382,04881,42581,75180,22081,27079,54677,20274,23872,40670,73869,13467,15165,48564,09663,93362,13360,75159,61458,30056,80355,24655,38553,73849,59448,08445,50044,42943,76942,84040,75539,75837,80936,54334,48632,81730,24330,20628,53827,84428,59026,20825,87225,65524,83725,34330,35929,70130,980-13,521,42849,198279,702267,99510,773,973270,018272,271283,491275,155251,515246,086254,383273,223242,227222,991204,954212,559244,187264,535220,503218,134217,540202,66500000000000000000000000000000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue6,171
Cost of Revenue-1,380
Gross Profit4,7914,791
 
Operating Income (+$)
Gross Profit4,791
Operating Expense-82,490
Operating Income-76,319-77,699
 
Operating Expense (+$)
Research Development54,037
Selling General Administrative22,108
Selling And Marketing Expenses0
Operating Expense82,49076,145
 
Net Interest Income (+$)
Interest Income6,585
Interest Expense-137
Other Finance Cost-0
Net Interest Income6,448
 
Pretax Income (+$)
Operating Income-76,319
Net Interest Income6,448
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-69,920-82,718
EBIT - interestExpense = -69,920
-69,920
-69,783
Interest Expense137
Earnings Before Interest and Taxes (EBIT)-69,783-69,783
Earnings Before Interest and Taxes (EBITDA)-68,403
 
After tax Income (+$)
Income Before Tax-69,920
Tax Provision-0
Net Income From Continuing Ops-69,920-69,920
Net Income-69,920
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses82,490
Total Other Income/Expenses Net6,399-6,448
 

Technical Analysis of Arbutus Biopharma Corp
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Arbutus Biopharma Corp. The general trend of Arbutus Biopharma Corp is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Arbutus Biopharma Corp's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Arbutus Biopharma Corp Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Arbutus Biopharma Corp.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: .

The bearish price targets are: 4.3491 > 3.79 > 3.79.

Know someone who trades $ABUS? Share this with them.👇

Arbutus Biopharma Corp Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Arbutus Biopharma Corp. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Arbutus Biopharma Corp Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Arbutus Biopharma Corp. The current macd is 0.28989096.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Arbutus Biopharma Corp price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Arbutus Biopharma Corp. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Arbutus Biopharma Corp price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Arbutus Biopharma Corp Daily Moving Average Convergence/Divergence (MACD) ChartArbutus Biopharma Corp Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Arbutus Biopharma Corp. The current adx is 58.15.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Arbutus Biopharma Corp shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Arbutus Biopharma Corp Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Arbutus Biopharma Corp. The current sar is 5.071092.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Arbutus Biopharma Corp Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Arbutus Biopharma Corp. The current rsi is 63.81. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Arbutus Biopharma Corp Daily Relative Strength Index (RSI) ChartArbutus Biopharma Corp Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Arbutus Biopharma Corp. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Arbutus Biopharma Corp price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Arbutus Biopharma Corp Daily Stochastic Oscillator ChartArbutus Biopharma Corp Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Arbutus Biopharma Corp. The current cci is 74.83.

Arbutus Biopharma Corp Daily Commodity Channel Index (CCI) ChartArbutus Biopharma Corp Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Arbutus Biopharma Corp. The current cmo is 22.22.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Arbutus Biopharma Corp Daily Chande Momentum Oscillator (CMO) ChartArbutus Biopharma Corp Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Arbutus Biopharma Corp. The current willr is -44.66666667.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Arbutus Biopharma Corp is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Arbutus Biopharma Corp Daily Williams %R ChartArbutus Biopharma Corp Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Arbutus Biopharma Corp.

Arbutus Biopharma Corp Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Arbutus Biopharma Corp. The current atr is 0.21998446.

Arbutus Biopharma Corp Daily Average True Range (ATR) ChartArbutus Biopharma Corp Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Arbutus Biopharma Corp. The current obv is 58,684,439.

Arbutus Biopharma Corp Daily On-Balance Volume (OBV) ChartArbutus Biopharma Corp Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Arbutus Biopharma Corp. The current mfi is 74.69.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Arbutus Biopharma Corp Daily Money Flow Index (MFI) ChartArbutus Biopharma Corp Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Arbutus Biopharma Corp.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-01STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-05-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-11MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-06-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-26BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-08-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-07MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-08MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-08-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-08-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-08-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-08-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-25MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-08-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-27MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-02STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-09-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-09-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-10ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-11STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-09-16MFI SHORT ENTRY LONG CLOSE80 crossover to downside

6.3. Candlestick Patterns

Arbutus Biopharma Corp Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Arbutus Biopharma Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5063.811
Ma 20Greater thanMa 504.028
Ma 50Greater thanMa 1003.587
Ma 100Greater thanMa 2003.465
OpenGreater thanClose4.382
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Arbutus Biopharma Corp with someone you think should read this too:
  • Are you bullish or bearish on Arbutus Biopharma Corp? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Arbutus Biopharma Corp? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Arbutus Biopharma Corp

I send you an email if I find something interesting about Arbutus Biopharma Corp.


Comments

How you think about this?

Leave a comment

Stay informed about Arbutus Biopharma Corp.

Receive notifications about Arbutus Biopharma Corp in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.